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ProductivityPichia pastoris, a methylotrophic yeast, is an established system for the production of heterologous proteins, par-
ticularly biopharmaceuticals and industrial enzymes. To maximise and optimise the production of recombinant
products, recent molecular research has focused on numerous issues including the design of expression vectors,
optimisation of gene copy number, co-expression of secretory proteins such as chaperones, engineering of glyco-
sylation and secretory pathways, etc. However, the physiological effects of different cultivation strategies are
often difﬁcult to separate from the molecular effects of the gene construct (e.g., cellular stress through over-
expression or incorrect post-translational processing). Hence, overall system optimisation is difﬁcult, even
though it is urgently required in order to describe and understand the behaviour of new molecular constructs.
This review focuses on particular aspects of recombinant protein production related to variations in biomass
growth and their implications for strain design and screening, as well as on the concept of rational comparisons
between cultivation systems for the development of speciﬁc production processes in bioreactors. The relation-
ship between speciﬁc formation rates of secreted recombinant proteins, qp, and speciﬁc growth rates, μ, has
been analysed in a conceptual attempt to compare different systems, particularly those based on AOX1/methanol
and GAP/glucose, and this has now evolved into a pivotal concept for bioprocess engineering of P. pastoris.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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As a production system, the methylotrophic yeast Pichia pastoris
is distinguished by very high biomass concentrations, its potential to
produce large quantities of correctly processed recombinant proteins
(intracellularly or secreted) of either prokaryotic or eukaryotic origins,
and containing a tightly regulated AOX1-promoter (Cereghino and
Cregg, 2000). Extensive lists of proteins that have been successfully
produced with P. pastoris highlight the increasing future relevance of
this microbial production system (reviewed in Ahmad et al., 2014;
Calik et al., 2015; Cereghino and Cregg, 2000; Li et al., 2007;
Macauley-Patrick et al., 2005). Due to heightened interest in its applica-
tion, newgenetic tools for P. pastorishave been developed (Ahmadet al.,
2014; Delic et al., 2014; Vogl and Glieder, 2013; Vogl et al., 2013), and
thus the availability of new strains has intensiﬁed the need for a system-
atic design of cultivation and production processes with this yeast
(Buchetics et al., 2011; Potgieter et al., 2010; Rebnegger et al., 2014).
Existing shortcomings of the P. pastoris production system are ad-
dressed either by genetic strain engineering (Idiris et al., 2010;
Puxbaum et al., 2015) or at the level of the cultivation process in
bioreactors. Generally, bioprocess design aims at identifying optimum
conditions for biomass growth and product formation, including pH,
temperature, oxygen and nutrient supply (e.g., Calik et al., 2015; Cos
et al., 2006; Jahic et al., 2006). Central to identifying the physiological
constraints of P. pastoris is the development of a suitablemode of adding
carbon and energy substrates, i.e., the feed proﬁle or feeding strategy
(Jahic et al., 2006; Khatri and Hoffmann, 2006b; Maurer et al., 2006;
Spadiut et al., 2014a; Zhang et al., 2007). Appropriate culture conditions
and feed strategies vary, depending on whether recombinant proteins
are produced under the control of the inducible AOX1-promoter in
Mut+ or MutS P. pastoris strains, or the constitutive GAP-promoter
(e.g., Calik et al., 2015; Maurer et al., 2006; Potgieter et al., 2010;
Yamawaki et al., 2007).
Available cultivation protocols are mainly based on those described
in the commercial Invitrogen expression kit (Invitrogen, 2002;
Stratton et al., 1998; Tolner et al., 2006). However, a recent trend is to
move away from standard protocols (i.e., ﬁxed recipes for growth-
dependent and growth-independent production kinetics) towards a
conceptual approach that allows for the development of a speciﬁc pro-
cess strategy that is tailored to both a particular product/genetic con-
struct combination and the characteristics of speciﬁc bioreactor
equipment (Maurer et al., 2006; Spadiut and Herwig, 2014; Zhang
et al., 2007). However, the concept itself should be generally applicable
and thus transferable between different strains and/or equipment.
As manufacturing processes aim at producing a maximum amount
of product with given quality speciﬁcations and in the minimum
process time (i.e., space–time-yield or volumetric productivity), speciﬁc
productivity qp, maximum biomass x · V, and productive time (i.e., time
between induction of product formation and harvest) are critical
inﬂuencing factors. In line with its aim of describing a pivotal concept
in bioprocess engineering, this review sharply focuses on the relation-
ship between biomass growth (expressed in terms of speciﬁc growth
rate μ) and product formation (expressed as speciﬁc productivity qp),
and validates this concept for process development with real experi-
mental data from P. pastoris processes. The advantage of the concept
presented in this review is using values of μ and qp that are strain specif-
ic and thus comparable between different systems (i.e., strain designsand bioreactors), and are independent of process-speciﬁc settings
such as biomass concentration, reactor volume or process time. In con-
trast, titres and rates of feed addition, which are typically published for
process comparison reasons, are not directly comparable because of
their interdependencies.
This review begins by explaining the meaning and use of the physi-
ological characteristics of biomass growth and recombinant protein for-
mation, as well as their implications for reducing the number of clones
during screening in batch mode. It further exempliﬁes formation kinet-
ics (i.e., the qp(μ)-relationships) published in the literature for several
recombinant proteins that are produced under the control of AOX1-
and GAP-promoters. The rationale behind a customisable process strat-
egy, starting with the physiological characterisation of a particular
strain, is that it can be logically adapted to any particular recombinant
strain and/or stirred bioreactor, and helps us to understand the differ-
ence between this and standard protocols. Finally, information com-
piled from the literature is translated into recommendations on best
practice, and future innovative development is depicted.
Recent literature claims a lack of strategies and workﬂows for sys-
tematic bioprocess development, which is required to shorten develop-
ment times and for increasing productivities (Knepper et al., 2014;
Posch and Herwig, 2014). This review therefore goes beyond standard
cultivation recipes towards concepts that enable an appropriate process
strategy to be rationally adapted to the particular features of a speciﬁc
recombinant strain, i.e., combinations of host, promoter and substrate,
product and gene copy number, as well as the individual characteristics
of the bioreactor equipment used. The information assembled takes a
process-oriented perspective that is not yet available in such focussed
depth in one review, and is reinforced by several other excellent general
overview articles on P. pastoris technology (Ahmad et al., 2014; Cos
et al., 2006; Delic et al., 2014; Gasser et al., 2008; Hartner and Glieder,
2006; Idiris et al., 2010; Jahic et al., 2006; Mattanovich et al., 2012,
2014; Spadiut et al., 2014a; Vogl and Glieder, 2013; Zhang et al., 2009).
2. Kinetics of biomass growth and recombinant protein formation
In general, two distinguishable operational strategies for P. pastoris
processes are derived from the most widely used promoters: inducible,
strongAOX1 (alcohol oxidase 1) or constitutive GAP (glyceraldehyde-3-
phosphate dehydrogenase). The major disadvantage of the mostly
favoured AOX1 over GAP is that it requires methanol for recombinant
protein production. Thus, methanol, added as a single carbon and ener-
gy source and metabolised by P. pastoris cells, is principally required
both for induction of product formation and growth to produce biomass
(NB. In contrast to current Pichia systems, the well-established E. coli
system, typically induced by IPTG, offers an advantage in controlling in-
duction and growth by two independent principles: by separately con-
trolling growth by addition of the C-substrate, and production by
addition of the IPTG-inducer).
Since genetic strain engineering (and overproduction of a heterolo-
gous protein) can considerably affect growth performance with any
(recombinant) P. pastoris strain, determinations of the key stoichiomet-
ric and kinetic characteristics of biomass growth and product formation
are the basis for the rational design of a production process in a bioreac-
tor. Thus, for each combination of genetic construction (i.e., mainly de-
termined by the promotor used and type of heterologous protein) and
culture conditions (i.e., substrate utilised, pH, T, etc.) an optimum
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mance is best. With AOX1-strains, this μopt, sought-after during process
development, typically lies at a certain value between conditions of no-
growth and maximum possible growth, μmax.
2.1. Biomass growth
Wild-type P. pastoris is able to growonmany different carbon and en-
ergy sources (Inan and Meagher, 2001), of which glycerol, glucose and
methanol are the most commonly used in manufacturing processes.
The choice of carbon-substrate and, therefore, the feasible operational
rangewith respect to speciﬁc growth rate (μ) and optimum productivity
(qp) is dependent on the chosen promoter. In addition, values of the
growth characteristics (i.e., μmax, Yx/s, ms, see nomenclature given in
Table 1) are crucial since they give a direct indication of whether the
strain is physiologically impaired due to the introduction and expression
of a foreign gene (Cos et al., 2006; Heyland et al., 2011; Hyka et al., 2010).
Heavily impaired strains tend to stop growing, die and lyse, which causes
problems in bioreactor operation because of heavy foaming as well as
impaired product quality due to the release of host proteins or intracel-
lular proteases (Jahic et al., 2003, 2006; Zhou and Zhang, 2002).
2.1.1. Phenotypes with respect to methanol utilisation
Strains expressing a heterologous gene under the control of the
AOX1-promoter utilise methanol, which is required both as an inducer,
and for biomass growth and production (Hartner et al., 2008). The oxi-
dation of methanol by alcohol oxidase is encoded by two genes, AOX1
and AOX2 (Cregg et al., 1989). Depending on whether one or other of
those genes is knocked out, three P. pastoris phenotypes are distinguish-
able (Cos et al., 2006): strains comprising functional versions of both
genes (Mut+, methanol utilising plus), mutants with an inactivated
AOX1 gene (Muts, methanol utilising slow) and mutants lacking both
AOX genes (Mut−, methanol utilising minus). Integration of a pAOX1-
based expression cassette into the P. pastoris genome at the AOX1
locus allows either integration into or replacement of the AOX1-gene,
resulting in a functional (Mut+ phenotype) or a dysfunctional AOX1
gene (Muts phenotype). Mut− strains, however, are not able to
metabolise methanol, which then only acts as an inducing agent forTable 1
Nomenclature.
Abbreviation Unit Description
cp mg l−1 Product titre, concentration of product (in supernatant)
cp · Vs mg Amount of product
CPR mol h−1 Carbon dioxide production rate
F g h−1 Feed rate
F0 g h−1 Initial feed rate
ms g g−1 h−1 Speciﬁc maintenance rate
μ h−1 Speciﬁc growth rate
μmax h−1 Maximum speciﬁc growth rate
qp mg g−1 h−1 Speciﬁc productivity (speciﬁc rate of product formation)
qp,max mg g−1 h−1 Maximum speciﬁc productivity (speciﬁc rate of
product formation)
qs g g−1 h−1 Speciﬁc rate of substrate utilisation
qs,max g g−1 h−1 Maximum speciﬁc substrate utilisation rate
rp mg l−1 h−1 Volumetric productivity (space–time-yield)
s g l−1 (Residual) concentration of substrate in the reactor
s0 g l−1 Initial substrate concentration
t h Process time
V l Working volume
V0 l Initial working volume
Vs l Volume of supernatant
win g g−1 Mass fraction of substrate in the feed solution
x g l−1 Concentration of biomass
x · V g Mass of biomass
x0 g l−1 Initial biomass concentration
Yp/x mg g−1 Observed yield (product/biomass)
Yx/s g g−1 Observed yield (biomass/substrate)
Yx/s,max g g−1 Maximum yield (biomass/substrate)recombinant protein production (Chiruvolu et al., 1997). A commercial-
ly available strain, MC100-3 (his4 arg4 aox1Δ:SARG4 aox2Δ:Phis4), has
both AOX genes deleted but retains the ability to induce recombinant
protein production at high levels using the AOX1-promoter (Cregg
and Madden, 1989). Such a strain represents the ﬁrst example of
decoupling growth and protein production during the same cultivation
phase, since co-feeding with a second carbon source, such as glucose, is
necessary (i.e., in addition to a certain concentration of methanol that is
not metabolised and acts only as an inducer; Chiruvolu et al., 1997).
However, more recent literature reveals that these strains are, for
non-disclosed reasons, not currently in use. A further problem with
such a system can be the need to monitor (and continuously adjust)
the methanol concentration as it is stripped from the culture medium.
With excessmethanol as a substrate, at 30 °C, Mut+ strains achieved
maximum speciﬁc growth rates of up to 0.15 h−1 (Kobayashi et al.,
2000). For MutS strains, typical μmax-values were considerably lower,
e.g., up to 0.035 h−1 (Brierley et al., 1990). Commonly observed effects
of μmax values decreasing at cultivation temperatures below 30 °C,
depending on the composition of culture medium, also apply to
P. pastoris (Curvers et al., 2001b; Kovarova et al., 1996). A particular
strain's ability to achieve a given μmax value has different relevance in
batch versus fedbatch culture modes. During a fedbatch process, μ is
controlled at its optimum with respect to growth or production. Thus,
under well-controlled fedbatch conditions, the same (low) μ-value can
be set for either MutS or Mut+ strains. The essential beneﬁt of working
with a MutS strain is that, in the case of methanol accumulation, this
strain does not accelerate its growth as fast as Mut+ would do, and
hence large scale manufacturing with MutS may be easier (Cos et al.,
2005; Stratton et al., 1998).
2.1.2. Relation of biomass growth and heterologous protein production
During batch cultivation, in which substrate is available in excess,
biomass growth is unrestricted and growth characteristics can be deter-
mined directly (Table 2, Fig. 1). With glycerol or glucose, P. pastoris
grows signiﬁcantly faster (i.e., 1.7–8.5 times faster for the strains given
in Table 2) than with methanol. Typical diauxic behaviour is observed
in batch cultures (i.e., glucose or glycerol repress the utilisation ofmeth-
anol and these substrates are therefore used sequentially) (Jungo et al.,
2007). Strains engineered for recombinant production of a heterologous
protein often exhibit maximum speciﬁc growth rates (Table 2) signiﬁ-
cantly lower than those observed with a non-engineered host strain.
Recombinant Mut+ strains are reported to grow in excess methanol at
a wide range of μ from 0.028 h−1 to 0.154 h−1, and MutS strains at
0.011 h−1 to 0.035 h−1. Decreased maximum speciﬁc growth rates
are most probably related to genetic burdens introduced by strain engi-
neering and/or metabolic burdens of recombinant protein production
(Gasser et al., 2008; Glick, 1995; Heyland et al., 2011). During batch
growth with glucose, μmax varied from 0.28 h−1 to 0.16 h−1 for strains
differing with respect to productivity, whereas the best-producer
strains grew slower (Heyland et al., 2011). Furthermore the speciﬁc glu-
cose uptake rate (qs) did not change in accordance with the speciﬁc
growth rate, and TCA cycle activity was found to be constant irrespec-
tive of signiﬁcantly reduced growth rates. This data suggests that the
additional resources required for recombinant protein production
resulted in reduced speciﬁc growth rates (Heyland et al., 2011).
Regarding strain design, high levels of expression of a protein may
also have a detrimental effect on cell metabolism, but this might be bet-
ter tolerated by the host at low gene dosage; hence, the assumption that
‘higher gene dosage equals higher production’ is not necessarily true
(Aw and Polizzi, 2013). For instance, Mut+ strains with more than 12
recombinant gene copies had lower substrate utilisation and speciﬁc
growth rates (0.01 h−1 to 0.02 h−1) than strainswith fewer gene copies
(0.025 h−1 to 0.029 h−1) (Zhu et al., 2009). A similar effect was not ob-
served in MutS strains: both single- and multi-copy MutS strains exhib-
ited comparable growth rates while Mut+ single-copy strains grew
faster than Mut+ multi-copy strains (Table 2) (Cos et al., 2005).
Table 2
Kinetic and stoichiometric characteristics of Pichia pastorisMut+ and Muts strains.
If not otherwise stated, values are typically based on cultivation of recombinant strains at 30 °C with the listed carbon sources. The table entries are listed in the order of decreasingmax-
imum speciﬁc growth rates (μmax) achieved with the inducing substrate (methanol) while producing a recombinant protein (marked in bold). Data listed for glycerol relate to biomass
growth without product formation. Yx/s (biomass to substrate yield) andms (speciﬁc maintenance rate) are based on cell dry weight in grams.
Methanol Glycerol Heterologous product
(origin)
Gene copy number Strain Reference
μmax
(h−1)
Yx/s
(g g−1)
ms
(g g−1 h−1)
μmax
(h−1)
Yx/s
(g g−1)
ms
(g g−1 h−1)
Mut+ 0.154 0.38 0.023 Serum albumin (human) 2 GS115 Kobayashi et al. (2000)
0.14 Lysozyme (bovine) NA GS115 Brierley et al. (1990)
0.14 0.42 0.014 0.24 0.61 0.009 Avidin NA GS115 Jungo et al. (2006)
0.12 0.41 0.28a 0.72a Trypsinogen (pocine) NA X-33 Paulova et al. (2012)
0.101 0.38 0.011 0.45 Insulin precursor (porcine) 6 to 8 GS115 Hang et al. (2008)
0.10–0.13 0.15 0.20–0.29 0.45–0.47 Serum albumin (human) NA GS115 Ren et al. (2003)
0.07 0.33b 0.016b α-Galactosidase (coffee bean) NA GS115 Zhang et al. (2005)
0.051 0.18 0.5 Lipase (Rhizopus oryzae) Single X-33 Cos et al. (2005)
0.028 0.18 0.5 Lipase (Rhizopus oryzae) Multi X-33 Cos et al. (2005)
– 0.16 0.03 0.21 0.43 0.032 hG-CSF (human) 2 GS115 Bhatacharya et al. (2007)
MutS 0.035 Lysozyme (bovine) NA GS115 Brierley et al. (1990)
0.018 0.18 0.5 Lipase (Rhizopus oryzae) Multi X-33 Cos et al. (2005)
0.015 Lipase (Rhizopus oryzae) Single KM71 Cos et al. (2006)
0.014 0.18 0.5 Lipase (Rhizopus oryzae) Single X-33 Cos et al. (2005)
0.011 0.30 0.026 0.093 0.619 Mini proinsulin Multi GS115 Pais et al. (2003)
NA not available.
a Values for glucose as substrate.
b Published parameter adapted from wet cell weight to dry cell weight by a factor of four.
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In-depth analysis of published data on recombinant protein produc-
tion with P. pastoris drives the following recommendations:
• Maximum speciﬁc growth rate is a critical factor indicating impaired
physiology due to recombinant protein production (or merely intro-
duction of the foreign gene into the strain). A careful determination
of μmax (using several data points for various substrates, e.g., glucose,
glycerol, and methanol) is therefore mandatory in commencing any
process development.
• Recombinant Mut+ strains are reported to grow in excess methanol
at a wide range of μ from 0.028 h−1 to 0.154 h−1, and MutS
strains in a narrower range from 0.011 to 0.035 h−1. Therefore,
under well-controlled fedbatch conditions, the same (low) μ-value
can be set (and controlled) for either MutS or Mut+ strains. The fur-
ther advantage of processes with MutS strains is their robustness
with respect to overfeeding with methanol.Fig. 1. Calculation box: speciﬁc growth rate (μ) andmaximum speciﬁc growth rate (μmax). Speci
logarithmof biomass (x · V). A constant speciﬁc growth rate of (0.038±0.001) h−1 was determ
B (unpublished results).2.2. Production kinetics
The speciﬁc rate of biomass growth (μ) is a critical factor in enhancing
product formation (Kobayashi et al., 2000; Potgieter et al., 2010; Schenk
et al., 2008; Sinha et al., 2007; Zhang et al., 2000, 2005) aswell as affecting
product quality (Schenk et al., 2008;Wu et al., 2011). The relationship be-
tween speciﬁc productivity (qp in mg product built per g cell dry weight
and per hour, Figs. 2, 3) and μ (h−1) reﬂects the equilibriumbetween var-
ious processes in a cell until the product is secreted (i.e., induction of gene
expression, translation, protein folding and degradation in the endoplas-
mic reticulum,ﬂux of folded protein out of the ER, and trafﬁcking through
the secretory machinery). This relationship, also termed ‘production ki-
netics’ (Fig. 2), is essential for the design of production strategies in
which growth is retained at a certain optimum μ-value by the controlled
addition of carbon-substrate in fedbatch mode (Barrigon et al., 2015).
Since broad and systematic experience in the production of recombinant
enzymeswith P. pastoris is not yet available, the qp(μ)-relationship (Fig. 2)ﬁc growth rate can be calculated similarly for batch and fedbatch cultivations based on the
ined for 71 h of fedbatch productionwith Pichia pastoris secreting Candida antarctica lipase
0.30
0.25
0.20
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A: antibody / Fab fragment B: serum albumin
Fig. 2. Production kinetics forAOX1 andGAP-regulated expression. Published kinetics of secreted antibody/Fab fragments (A) and serumalbumin (B) are compared. Recombinant products
under control of the AOX1-promoter andmethanol (open symbols) are distinguished fromGAP-promoterwith glucose as a substrate (black symbols). Culture conditions are summarised
in Table 2. A: (○) Potgieter et al. (2010); (◇) Yamawaki et al. (2007), 10% DO-stat; (□) Yamawaki et al. (2007), 3.9 g l−1 methanol-stat; (●) Maurer et al. (2006); (▲) Buchetics et al.
(2011). B: (△) Kobayashi et al. (2000); (■) Rebnegger et al. (2014).
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et al., 2010). Such experimental approaches for establishing product for-
mation kinetics are described in Section 3.2.2.
An exemplary overview of published data on optimum speciﬁc
growth rates at which the highest speciﬁc productivity (qp,max) was
reached for different strains, promoters and products, is given in
Table 3. Typically, production kinetics controlled by the AOX1-
promotor, utilising methanol or mixtures of substrates with methanol,
were investigated for μ b 0.08 h−1 (Curvers et al., 2001b; Zhang et al.,Fig. 3. Calculation box: descrip2005) or even μ b 0.03 h−1 (Hang et al., 2008; Kobayashi et al., 2000;
Min et al., 2010; Potgieter et al., 2010). Only two kinetic-relationships
with low qp-values (b0.03 mg l−1 h−1) were investigated up to a μ of
0.14 h−1 (Jungo et al., 2006; Schenk et al., 2008). For processes in
which production is controlled by the GAP-promoter, utilising glucose
as a growth and energy substrate, speciﬁc growth rates of up to
0.2 h−1 were investigated (Khasa et al., 2007).
Generally, a multitude of relationships between production and
growth can be found in the literature, i.e., increasingly or decreasinglytion of product formation.
Table 3
Kinetics of recombinant secreted products.
The entries are listed in increasing order of optimal speciﬁc growth rates (μ) for recombinant product formation. Formation kinetics of antibodies and serum albumin are compared in
detail in Fig. 1 (marked in bold). Maximum speciﬁc product formation rates (qp,max) are expressed as milligrams of product synthesised per gram of cell dry weight per hour.
Promoter Cultivation conditions Product formation kinetics Reference
Utilisation Medium Temp.
(°c)
pH Mode μ-range
(h−1)
μ(qp,max)
(h−1)
qp,max
(mg g−1 h−1)
Kinetics Heterologous product
(origin)
AOX met (Mut+) Deﬁned 30.0 5.85 Fedbatch 0.002–0.027 0.002 0.26 Negatively
growth related
Serum albumin
(human)
Kobayashi et al.
(2000)
Fig. 4
AOX met (Mut+) Deﬁned 30.0 5.0 Fedbatch 0.004–0.021 0.004 0.023 Negatively
growth related
Saxatilin (Gloydius
saxalitis)
Min et al. (2010) Table 2
AOX met (Mut+) Deﬁned 30.0 5.0 Fedbatch 0.006–0.01 0.01 0.2 Growth coupleda hG-CSF (human) Bhatacharya
et al. (2007)
Fig. 7
AOX met (Mut+) Complex 24.0 6.5 Fedbatch 0.003–0.03 0.014 0.17b Bell shaped Antibodyc(IgG1) Potgieter et al.
(2010)
Fig. 3
AOX met (Mut+) Deﬁned 30.0 5.0 Fedbatch 0.003–0.023 0.016 0.1 Bell shaped Insulin precursor
(porcine)
Hang et al.
(2008)
Fig. 3
AOX met (Mut+) Deﬁned 30.0 5.0 Continuousd 0.009–0.05 0.02 0.12 Bell shaped scFv fragment
(anti-bisphenol A)
Yamawaki et al.
(2007)
Fig. 7
AOX met (Mut+) Deﬁned 30.0 5.0 Fedbatch 0.015–0.06 0.03 0.42b Bell shaped
(complex)
α-Galactosidase
(coffee bean)
Zhang et al.
(2005)
Fig. 3
AOX met (Mut+) Deﬁned 30.0 5.0 Continuouse 0.007–0.05 0.04 0.004 Linear (oxygen
limited)
scFv fragment
(anti-bisphenol A)
Yamawaki et al.
(2007)
Fig. 7
AOX met:gluf
(Mut+)
Deﬁned 30.0 5.9 Continuous 0.03–0.20 0.07 0.69 Bell shaped Trypsinogen (porcine) Paulova et al.
(2012)
Fig. 2
AOX met (Mut+) Deﬁned 27.5 5.0 Continuous 0.04–0.08 0.08 0.24 Growth coupled Chymotrypsinogen B
(human)
Curvers et al.
(2001b)
Fig. 6
AOX met:gly
(MutS)
Deﬁned NA NA Continuous 0.01–0.09 0.09 0.07 Growth coupled Antifreeze protein
(sea raven)
d'Anjou and
Daugulis (2001)
Fig. 2
AOX met (Mut+) Deﬁned 30.0 5.0 Continuous 0.03–0.12 0.12 0.03 Growth coupled Avidin Jungo et al.
(2006)
Fig. 8
AOX met (Mut+) Deﬁned 30.0 5.0 Fedbatch 0.02–0.14 0.14 0.03 Growth coupled Avidin Schenk et al.
(2008)
Fig. 2
GAP glu NA 25.0 5.85 Continuous 0.015–0.15 0.15 0.15 Growth coupled Serum albumin
(human)
Rebnegger et al.
(2014)
Fig. 1
GAP glu Deﬁned 25.0 5.0 Continuous 0.02–0.19 0.19 0.049 Growth coupled Fab fragment (anti-HIV
antibody 2F5)
Maurer et al.
(2006)
Fig. 1
GAP glu Deﬁned 25.0 5.0 Continuous 0.02–0.19 0.19 0.05 Growth coupled Fab fragment (human
antibody 3H6)
Buchetics et al.
(2011)
Fig. 2
GAP glu Complex 30.0 5.0 Continuous 0.02–0.20 0.20 0.49 Growth coupled hG-CSF (human) Khasa et al.
(2007)
Fig. 5
NA not available.
a Computed relationship.
b Published parameter adapted from wet cell weight to cell dry weight by factor four.
c Glycoengineered strain.
d Constant methanol concentration of 3.9 g l−1.
e Constant dissolved oxygen at 10%.
f Substrate mixture of 40:60 carbon of methanol:carbon of glucose.
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et al., 2001b; Graslund et al., 2008; Hang et al., 2008; Jungo et al.,
2006; Kobayashi et al., 2000; Min et al., 2010; Potgieter et al., 2010;
Schenk et al., 2008; Zhang et al., 2005). Nevertheless, for strains contain-
ing the GAP-promoter, product formation was found to increase with
speciﬁc growth rates almost up to μmax (Khasa et al., 2007; Maurer
et al., 2006). For AOX1 Mut+ strains cultured with methanol, the opti-
mum speciﬁc growth rate for product formation (μopt at qp,max) ranged
from low μ-values of 0.002 h−1 to values up to μmax of 0.14 h−1
(Table 3). Processes with low optimal μ-values b 0.004 h−1 showed
negative growth-related relationships between production and growth
(Kobayashi et al., 2000; Min et al., 2010), processes with optimal μ-
values between 0.014 h−1 and 0.07 h−1 tended towards bell-shaped
or complex relationships (Hang et al., 2008; Paulova et al., 2012;
Potgieter et al., 2010; Yamawaki et al., 2007; Zhang et al., 2005) and
for processes with μopt N 0.08 h−1, product formation was directly pro-
portional to biomass growth (Curvers et al., 2001b; d'Anjou and
Daugulis, 2001; Jungo et al., 2006; Schenk et al., 2008). Interestingly,
AOX1-controlled product formation, performedwith substratemixtures
of either methanol and glucose (Paulova et al., 2012) or methanol and
glycerol (d'Anjou and Daugulis, 2001), showed higher speciﬁc growth
rates and kinetics similar to GAP-processes with glucose.Selecting data from Table 3 for two different products (as represen-
tatives of product classes), an Fab-fragment and serum albumin,
great variability in kinetic relationships was demonstrated (Fig. 2).
Production of an Fab-fragment of anti-HIV antibody 2F5 (Maurer et al.,
2006) and an Fab-fragment of the human antibody 3H6 (Buchetics
et al., 2011) was both controlled by the GAP-promoter, and glucose
was used as a substrate during continuous culture. For both recombi-
nant products (only varying in the variable antigen binding site), specif-
ic product formation rates were comparable. For these processes, GAP-
controlled production of secreted Fab-fragments and biomass growth
were associated in a hyperbolic-like relationship. In contrast, secretion
of glycosylated antibody (IgG1 with heavy and light chain) by a glyco-
engineered P. pastoris strain under the control of AOX1, in a culture
with methanol, was negatively growth-associated (Potgieter et al.,
2010). With methanol as a substrate, maximum speciﬁc productivity
was reached at signiﬁcantly lower speciﬁc growth rates than for GAP-
controlled production of Fab fragments. For serumalbumin, opposite re-
lationships were observed in cultures with methanol or glucose. AOX1-
controlled production with methanol as a substrate showed negative
growth-related product formation (Kobayashi et al., 2000) whereas
for glucose and the GAP-promoter, positive growth-related product for-
mation was observed (Rebnegger et al., 2014).
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Experimental data on recombinant protein productionwith P. pastoris,
as published in the literature so far, reﬂect the following:
• Different production kinetics was determined in similar categories of
recombinant products (i.e., several antibodies or serum albumin,
etc.). The trend is towards a greater similarity between kinetics for dif-
ferent products built by strains of principally the same design and
under the same culture conditions (i.e., promoter and substrate com-
bination) than for recombinant products in the same class (Fig. 2).
Therefore, when developing processes for strains which have not yet
been characterised, promoter use informs decisions on appropriate
substrates and process strategies.
• GAP-controlled production of secreted proteins is growth-associated;
it typically increases (linearly, directly proportional) with increasing
speciﬁc growth rates until close to μmax.
In direct analogy to kinetics of GAP-controlled production, at a
ﬁrst glance it would seem sensible to design high-performance pro-
cess strategies at the maximum growth performance close to μmax.
However, controlling μ in a decreasing manner as time proceeds
over the cultivation process is recommended as this strategy leads
to the highest productivities and titres (see Section 3.3 for background
rationale).
• Product formation kinetics of AOX1-controlled protein production
(in contrast to GAP-controlled) is bell-shaped, which may well
be related to saturation of the secretory pathway due to high ex-
pression levels (promoter and copy number) or to methanol, a
less favourable substrate, being used. Moreover, a multitude of
relationships between production and growth were found for
AOX1-strains.
Despite the existing knowledge gap for AOX1-controlled product
formation, process design at a low speciﬁc growth rate of
b0.04 h−1 is particularly suitable for reaching high titres and
productivities.
3. Development and implementation of an optimum
process strategy
In general, recombinant protein production responds to variations in
biomass growth. However, cultivation conditions during the initial
screening experiments and those in the production process in bioreac-
tors often differ signiﬁcantly. Translation of screening results and
further process optimisation to match bioreactor conditions are, there-
fore, difﬁcult and laborious tasks (Hesketh et al., 2013; Hohenblum
et al., 2004; Marx et al., 2009; Resina et al., 2009). A crucial aspect,
still not adequately covered in the current literature, is the need
for screening under ‘industrially relevant conditions’; this is rarely in-
corporated into current screening procedures. The major steps from
the construction of a recombinant P. pastoris strain to the implementa-
tion of a production process, which are illuminated in this review article,
are:
• screening of clones (or different constructs) with the aim of reducing
their number (Section 3.1);
• further characterisation of ‘typical’ behaviour observed in ﬁrst screen-
ings in order to obtain in-depth knowledge of biomass growth and
product formation (Section 3.2);
• implementation of a production process in fedbatchmode (Section 3.3).
In this review, we consider medium composition, pH and tempera-
ture as already being set at their optima with respect to both strain
physiology and possible limits of the equipment. If of interest, these as-
pects are described in some detail elsewhere (Calik et al., 2015; Cos
et al., 2006).3.1. Screening in small scale
The ‘best producer’ (clone or strain) is typically identiﬁed at a very
early stage of process development, and is then propagated throughout
the remaining developmental phases of the production process of a
particular protein. In general, initial high-throughput screening is ap-
plied to correct for signiﬁcant clonal variability (inherent in current
P. pastoris transformation protocols) and to reduce the considerable ex-
perimental loadwhen performing bioreactor experiments. As screening
more than 2–4 clones under production conditions in bioreactors
is labour-intensive and, thus, impractical, only a few of the ‘best’
performing P. pastoris transformants are typically selected from the
initial large population (up to several hundred) (Weis et al., 2004).
However, interpretation and direct transferability of results from
batch culture screening, in shake ﬂasks or deep-well plates, to fedbatch
bioreactor cultures is essential (Barnard et al., 2010; Hemmerich et al.,
2014; Wilming et al., 2014). Moreover, it is notable how published pro-
tocols for high-throughput screening still treat this step as being sepa-
rate from core process development.
3.1.1. Screening in batch mode
Screening for and selecting clones is a critical step in the develop-
ment of a process for producing a heterologous protein in P. pastoris.
In recent years, screening of microorganisms in general has beneﬁted
from a number of technological advances, allowing expansion, even in
very simple laboratory settings, of the number of parallel batch-type ex-
periments that can be carried out using 96-deep-well plates or similar
devices (Camattari et al., 2014; Weinhandl et al., 2012; Weis et al.,
2004).
For AOX1-controlled production, methanol is typically pulsed re-
peatedly after complete depletion of the pulsed glucose substrate in
order to maintain a residual substrate concentration within pre-
determined upper and lower concentration limits (Weis et al., 2004).
During phases of substrate excess (which occur immediately after puls-
ing of the substrate), biomass growswith a speciﬁc growth rate close to
itsmaximum (μmax). Between subsequent pulses, i.e., after substrate de-
pletion, biomass growth typically declines to 0 h−1 and biomass con-
centration stagnates (Fig. 4).
Unlike pulsed strategies applied in screening, in a bioreactor, the
speciﬁc growth rate is controlled by the rate of substrate addition at
a deﬁned value lower than or equal to its maximum (μmax). In
this sense, screening in 96-well plates does not reﬂect the conditions
of (industrial) fedbatch cultivation. The optimum for AOX1-controlled
product formation, according to current literature on kinetics (Table 3),
is often considerably below μmax (Fig. 4). However, for GAP-controlled
product formation, optimum speciﬁc growth rate is often near to μmax,
which is also reached during screening (Table 3). The consequence may
be a serious failure to identify clones thatwill become true ‘top producers’
under large-scale cultivation conditions.However, identifying a clone able
to express large amounts of the desired product does not merely entail
selecting the ‘best producer’ that is appropriate for the ﬁnal production/
manufacturing scale (Mellitzer et al., 2012). High production is generally
detrimental to cell metabolism and cell survival (Holmes et al., 2009;
Jafari et al., 2011) and, thus, the ‘best’ producers from initial screening
may fail in bioreactor processes. Therefore, clustering clones according
to their performance (best, middle, low) and selecting representatives
for further characterisation in fedbatch processes is a way of dealing
with the high number of clones and simultaneously not losing those
with intrinsic variation before testing them in bioreactors (Mellitzer
et al., 2012).
For screening product formation controlled by the AOX1-promoter,
the use of the MutS phenotype can be advantageous (Cos et al., 2005)
and results generated in screenings are more likely to be transferable
between batch and fedbatch modes. The maximum speciﬁc growth
rate, and therefore the growth range on methanol, is smaller for MutS
than forMut+ strains. Examples of screening based on an advantageous
Fig. 4. Screening of clones for recombinant product formation by pulsed substrate addition.
Stylised kinetics (according to Table 3) of GAP- and AOX1-controlled product formation
are related to typical growth rates achieved during screeningwith substrate pulsed to an ex-
cess concentration (batch) and during substrate-limited mode in the bioreactor (fedbatch).
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P. pastoris are the production of G-protein coupled receptors (Singh
et al., 2012b), or intracellular, membrane-associated recombinant
products for fungal cytochrome P450 (Gudiminchi et al., 2013).
3.1.2. Overcoming drawbacks of current screening concepts
Production processes based on P. pastoris as an expression host are
typically more affected by clonal variability than those using either
Escherichia coli or Saccharomyces cerevisiae. There are three main
reasons for this speciﬁc feature of P. pastoris processes. Firstly, it iswide-
ly known that clonal differences are ampliﬁed in chromosomally-
integrated systems compared with episomal expression cassettes;
genomic perturbances represent a strong source of background noise
(Liachko and Dunham, 2014). Expression systems largely based on epi-
somal vectors, such as in E. coli or S. cerevisiae (at least during strain selec-
tion), are less prone to clonal variability due to genomic perturbance.
Secondly, and particularly pertinent to 96-well cultivation, results gainedfrom several small scale expression methods need to be carefully evalu-
ated due to the presence of ‘edge effects’, i.e., micro-variability at different
positions on a 96well plate, typically affecting clones growing inwells on
the outer edge (Lundholt et al., 2003). Such artifacts are observed with a
variety of different hosts and, though relevant, are not exclusive to
P. pastoris cultivations. A third effect impacting on clone behaviour in
small-scale cultivations is the fact that methanol induction causes a
strong transient response that is unique to each strain. Such a response
is, by its very nature, affected by cell-to-cell variability, and is difﬁcult
to normalisewhen considering a population of cells, even of the same ge-
netic clone, and represents phenotypic variability (Hesketh et al., 2013)
A bioreactor offers a much higher degree of process control andmon-
itoring possibilities than 96-well plates and shake ﬂasks. Themost impor-
tant difference between small-scale screening and bioreactor cultivation
is the ability to control the speciﬁc growth rate at values below its maxi-
mum. The gap between screening in batch culture mode (in shake ﬂasks
or deep-well plates) and the subsequently performed, labour-intensive,
bioreactor culture in fedbatch mode is currently addressed by small-
scale bioreactors and new feeding techniques (Barnard et al., 2010;
Lattermann and Buchs, 2014; Wilming et al., 2014). Down-scaled tech-
niques of substrate addition include pump-controlled feeding (Barnard
et al., 2010), release of glucose from a polymer (Hemmerich et al.,
2014) or by an enzyme (Panula-Perala et al., 2008), andmicroﬂuidic sys-
tems (Grunberger et al., 2014). These fedbatch-like screening small-scale
techniques better reﬂect conditions in the bioreactor to be used later in
production scale. However, polymer-based and enzymatic release sys-
tems are not available for the controlled release of methanol.
3.1.3. Recommendations for best practice in process development
The quote ‘You get what you screen for’ (Schmidt-Dannert and Ar-
nold, 1999) best reﬂects the dilemma of screening, which in principle
dictates a ‘quantity-over-quality’ approach. Nevertheless, the following
recommendations may facilitate good decisions based on information
obtained from screening:
• Proper screening is crucial and needs to be carried out before cultiva-
tion process development. However, culture conditions under high-
throughput screening (in shake ﬂasks or deep-well plates) are quite
different from fedbatch bioreactor cultures and therefore the ‘best’
producing clone identiﬁed in screening will not necessarily be the
best performing one in a bioreactor. Though its use is labour-
intensive, a bioreactor offers a much higher degree of process control
and monitoring than deep-well plates and shake ﬂasks.
• Typically, the optimum μ-values for product formationwithmethanol
(based on Table 3) are below maximum speciﬁc growth rates
achieved during pulsed screening in deep-well plates. Thus, in batch
cultures, optimum performance of Mut+/AOX1-strains cannot be
achieved and clusters of low, middle and high producing clones
should be selected for further testing.
• AOX1/MutS-strains, in which the ability to growwith methanol is de-
liberately impaired, exhibit a narrow range of speciﬁc growth rates,
and therefore the results of screening in batch mode (with methanol
pulses) may be transferable to a fedbatch production process.
• The results of screening GAP-strains in batch cultures are typically
transferable to fedbatch, since the production optimum is close to μmax.
3.2. Characterisation of biomass growth and product formation
Optimum conditions for the production of a recombinant protein in
P. pastoris differ according to the target molecule and promoter (Hyka
et al., 2010). To develop a production process for a newly constructed
strain of unknown behaviour, it is therefore essential to start with its
physiological characterisation. Since lacking a theoretical foundation,
such a characterisation requires an empirical understanding of the rela-
tionship between growth and product formation. Only based on
1185V. Looser et al. / Biotechnology Advances 33 (2015) 1177–1193knowledge of product formation kinetics can the appropriate produc-
tion conditions (i.e., both optimum range and time course of the speciﬁc
growth rates) be identiﬁed and implemented by controlled substrate
addition in a fedbatch process.
3.2.1. Determination of maximum speciﬁc growth rate
Maximum speciﬁc growth rate (μmax in units of h−1) is a critical
parameter for designing an appropriate and speciﬁc process strategy,
since it determines the maximum substrate consumption and thus,
the upper limit of substrate addition in a fedbatch feed proﬁle. However,
recombinant strains engineered for production of heterologous proteins
typically exhibit maximum speciﬁc growth rates (Table 2) that are sig-
niﬁcantly lower than those observed with a non-engineered strain.
In order to avoid substrate accumulation during fedbatch processes,
μ should be controlled at values below μmax, which are strain speciﬁc
and therefore, only achievable by experimentation. Maximum speciﬁc
growth rate can be determined directly during batch cultivation
(Fig. 1), in which substrate is available in excess and thus biomass
growth is unrestricted. For AOX1-controlled product formation, batch
experiments with an initial methanol pulse of 0.5% (v/v) and at least 4
consecutive pulses of 1.0% (v/v) methanol were performed to deter-
mine both themaximum speciﬁc growth rate and themaximum specif-
ic substrate uptake rate (Dietzsch et al., 2011b). With the initial
methanol pulse of 0.5% (v/v) clone-speciﬁc adaptation time tomethanol
was determined (Dietzsch et al., 2011b; Hesketh et al., 2013). Depend-
ing on the pulse-strategy, biomass growth either stagnates between
pulses (after substrate depletion, μ approaches 0 h−1) or growth ap-
proaching μmax is held throughout by immediate repeated pulses after
substrate depletion. In principle, complete substrate depletion is indi-
cated by a sudden increase in dissolved oxygen, and a drop in carbon di-
oxide concentrations, as monitored by off-gas analyses.
Dietzsch et al. (2011b) conducted two subsequent 1.0% (v/v) meth-
anol pulses (by immediate pulsing after substrate depletion) and re-
peated this approximately every 24 h. According to a Monod-type
relationship, maximum speciﬁc growth rates were reported to be
achieved at methanol concentrations of between 0.4% (v/v) and 0.5%
(v/v) (Curvers et al., 2001b; Kobayashi et al., 2000; Zhou and Zhang,
2002). A negative effect on cell growth was measured for methanol
concentrations of N0.4% (v/v) (Zhou and Zhang, 2002), N0.9% (v/v)
(Kobayashi et al., 2000), 1.5% (v/v) (Minning et al., 2001) and 3.0% (v/v)
(Khatri and Hoffmann, 2006a). However, with methanol concentrations
of b0.13% (v/v), cells grew according to the model of Curvers et al.
(2001b), with speciﬁc growth rates below μmax. Despite this rather incon-
sistent information on inhibitory concentrations of methanol, repeated
pulses of 1.0% (v/v)methanolwere found to be an appropriate concentra-
tion for determining μmax as well as qs,max.
However, production characteristics such as titres, yields and specif-
ic productivities obtained for this set of operational parameters used to
determine μmax for Mut+ and MutS strains/clones (Dietzsch et al.,
2011a; Krainer et al., 2012) do not reﬂect the highest possible produc-
tivity (Table 3). The best producing strain/clone could not therefore,
be selected based on qp-data obtained in such batch experiments.
3.2.2. Establishing production kinetics
Concerning characterisation of AOX1-controlled protein production,
bioreactor experiments are required to completely characterise the po-
tential of particular production clones. As a rational basis for process de-
velopment, the relationship between speciﬁc product formation rate
and the corresponding speciﬁc growth rate has to be determined de
novo and empirically for each strain/clone.
Generally, numerous laborious and time-consuming fedbatch
(Kobayashi et al., 2000; Potgieter et al., 2010) or continuous cultivations
(Jungo et al., 2006; Paulova et al., 2012) are performed at several differ-
ent pre-set μ-values to establish the desired qp(μ)-relationship (Fig. 2).
Fedbatch strategies for continuous addition of an organic carbon and
energy source are usually based on mathematical functions describingtime dependency on the rate of substrate addition (i.e., the feed proﬁle,
Fig. 5). In such strategies, substrate is added at predeﬁned rates that in-
crease or decrease following linear or exponential functions, or by
equivalent stepwise approximations (Fig. 5). Unlike pulsed strategies
(Dietzsch et al., 2011a), the speciﬁc growth rate is controlled by
the rate of substrate addition at a deﬁned value lower than or equal
to its maximum (μmax) (Zhang et al., 2007). The added substrate is
immediately utilised and therefore cells can only grow as fast as
the rate of substrate supply. In order to maintain a constant speciﬁc
growth rate over the entire course of a fedbatch process (Fig. 1),
the feed rate must be increased exponentially (the biomass also
grows exponentially) providing a constant amount of substrate
CDW−1 h−1 (Potgieter et al., 2009).
Optimum production conditions for AOX1-controlled recombinant
product formation with Mut+ strains are recommended to be deter-
mined at constant μ of 0.2 h−1, 0.4 h−1, 0.6 h−1 and 0.8 h−1, i.e., each
μ studied during a single exponential fedbatch cultivation (Zhang
et al., 2007). For MutS strains with a considerably lower strain-speciﬁc
μmax than 0.154 h−1 (Kobayashi et al., 2000) these pre-set μ values
would be too high. In Table 3 the authors referenced only two qp(μ)-re-
lationships for which the productivity maximum was at μ of about
0.14 h−1 (Jungo et al., 2006; Schenk et al., 2008). Typically production
kinetics were investigated for μ b 0.08 h−1 (Curvers et al., 2001b;
Zhang et al., 2005) or even below 0.03 h−1 (Hang et al., 2008;
Kobayashi et al., 2000; Min et al., 2010; Potgieter et al., 2010). Possi-
bly the relatively low speciﬁc growth rates were chosen since they
are favourable for the design of a production process with a high
titre and productivity (Mallem et al., 2014). For fully growth-
associated GAP-regulated production, kinetics was typically investi-
gated between 0.02 h−1 and 0.19 h−1 (Buchetics et al., 2011; Maurer
et al., 2006).
Establishing production kinetics with fedbatch cultivations at sever-
al different pre-set μ-values is laborious and time-consuming, and,
therefore, alternative approaches are being sought. The use of dynamic
process conditions for fast physiological strain characterisation are
summarised by reviews of Spadiut and Herwig (2014) and Spadiut
et al. (2013). Various dynamic fedbatch approaches currently under
development would allow the entire production range of μ to be
covered in a single experiment (Lüthy et al., 2011; Spadiut et al.,
2014b; Zalai et al., 2012). In these kinds of experiments, how prod-
uct formation may adapt with time has also been investigated
(Spadiut et al., 2014b). For example, a steep increase in speciﬁc
product formation rate was observed 40 h after methanol induction,
independent of the feeding strategy applied (Spadiut et al., 2014b).
Thus for approaches with constant or dynamically adapted μ-values,
time after induction in which speciﬁc productivity is stable must be
carefully determined in order to incorporate time dependency of prod-
uct formation into the design of the fedbatch production process
(Dietzsch et al., 2011a; Meyer and Schmidhalter, 2014; Spadiut et al.,
2014b).3.2.3. Recommendations for best practice in process development
The author's own experience in developing recombinant protein
production with P. pastoris, and supported by extensive literature re-
search, leads to the following recommendations:
• Physiological strain characterisation is themandatory ﬁrst step of any
product development. Since such characteristics are strain/clone-
speciﬁc, it is not predictable a priori and each strain should be exper-
imentally characterised de novo.
• The strain-speciﬁc maximum speciﬁc growth (μmax) rate is a critical
parameter restricting maximum possible feed addition in order to
avoid substrate accumulation. Repeated pulses of 1.0% (v/v)methanol
in batch cultures were found to be an appropriate and easy-to-handle
approach for determining μmax.
Fig. 5. Calculation box: Feed proﬁle.
1186 V. Looser et al. / Biotechnology Advances 33 (2015) 1177–1193• Knowledge of production kinetics, and the qp(μ)-relationship, are es-
sential to the design of a fedbatch production strategy in which
growth is controlled at a certain optimum μ-value b μmax by the con-
trolled addition of carbon-substrate.
• The qp(μ)-relationship cannot be established in batch cultures. For
AOX1-controlled product formation, fedbatch cultivations at pre-set
speciﬁc growth rates of 30%, 50% and 10% of μmax (i.e., this recommend-
ed order is practical and a fourth μ optional), which are achieved by ex-
ponential addition of substrate, should be held constant during the
experiment. Such a systematic development of three exponential
fedbatch processes would allow an early and efﬁcient assessment
of product formation kinetics, as well as avoiding unnecessary ad-
ditional cultivations and variations in the ﬁnal results. For fully
growth-associated, GAP-controlled production, fedbatch experi-
ments at relative speciﬁc growth rates of 25%, 50% and 75% of
μmax are recommended.
• For a long-term perspective, applications of dynamic fedbatch
feeding strategies are very promising and time-saving, but more
experience in establishing and producing reproducible results is
required than for exponential fedbatch cultivations.3.3. Establishing fedbatch production processes
Historically, the strong and tightly regulated AOX1-promoter
(pAOX1) has been mainly used for recombinant protein expression in
P. pastoris (Ahmad et al., 2014; Macauley-Patrick et al., 2005). Using
AOX1, methanol acts as an inducer for recombinant protein production
and, at the same time, as a carbon and energy source. Thus, induction
and production of heterologous protein are interconnected with sub-
strate utilisation and biomass growth. Moreover, purpose-engineered
AOX1-phenotypes that relate to the efﬁciency of methanol utilisation
(i.e., Mut+ andMutS strains, Section 2) represent an additional opportu-
nity in strain/process design (Cos et al., 2005; Pla et al., 2006). In this re-
spect, the P. pastoris expression system can be differentiated from, for
example, E. coli, in which promoters can be induced by an independent,
non-metabolisable agent. Consequently, P. pastoris production process-
es are more complex to control.
Commercially available expression kits by Invitrogen were crucial
for the development of the P. pastoris expression system and still dom-
inate the standard protocols for AOX1-controlled (i.e., inducible) pro-
duction of heterologous proteins (Invitrogen, 2002; Stratton et al.,
1187V. Looser et al. / Biotechnology Advances 33 (2015) 1177–11931998; Tolner et al., 2006). The typical P. pastoris cultivation process,
therefore, follows a three-stage strategy (Fig. 5):
• a batch phase for biomass growth with glycerol or glucose,
• a fedbatch phase for further biomass enhancement with glycerol or
glucose and
• an optional methanol-induced adaptation (transition) phase, which is
followed by a production phase in fedbatch mode.
3.3.1. Standard protocols for AOX1-controlled product formation
Conventional P. pastoris protocols describe feeding proﬁles for
‘simple’ recombinant protein production without customised design of
the feed proﬁle (Invitrogen, 2002; Stratton et al., 1998; Tolner et al.,
2006).What standard protocol is suitable for a particular strain depends
on the strain-speciﬁcmaximum speciﬁc growth ratewithmethanol and
the optimum μ-operational range for product formation.
From the three fedbatch protocols often used (Invitrogen, 2002;
Stratton et al., 1998; Tolner et al., 2006), time courses of biomass pro-
duction, and from these, speciﬁc growth rates were calculated and are
shown in Fig. 6. Time courses of biomass (in cell dry weight, CDW)Fig. 6.Operational ranges of standard protocols for AOX1-controlled product formation (Invitro
phase for biomass growthwith glycerol (A), a fedbatch phase for further biomass enhancement
methanol (C) are described. In the protocols, time courses are given in grams of carbon (of the co
courses of dry cell dry weight were calculated using biomass to substrate yields of 0.61 g g− 1
maintenance rate for methanol of 0.016 g g− 1 h− 1was used (Zhang et al., 2005). An initial gl
when 50 g l− 1 biomasswas reached.Third row: left axis corresponds to speciﬁc growth rates on
theoretical time courses of speciﬁc growth rates were calculated from the time courses of biomwere calculated using biomass to substrate yields of 0.61 g g−1 for glyc-
erol (Jungo et al., 2006) and 0.33 g g−1 for methanol (Zhang et al.,
2005). A maintenance rate for methanol of 0.016 g g−1 h−1 from a re-
combinant strain with μmax of 0.07 h−1 was used (Zhang et al., 2005).
These values were assumed to be typical but may, in fact, vary for
each new strain (Table 2). For all three protocols, the rate of methanol
addition was increased stepwise during the ﬁrst 10 h of production
and then kept constant (Fig. 6). When the feed rate is kept constant,
the amount of substrate CDW−1 h−1 actually decreases during the pro-
cess, resulting in a decreasing speciﬁc growth rate with time (Fig. 5,
Fig. 6). One of the main differences between the protocol of Tolner
et al. (2006), that was described in the Invitrogen protocol (2002),
and the P. pastoris protocol book by Stratton et al. (1998), is the lower
speciﬁc growth rate throughout the entire process following the initial
stepwise increase over approximately 6 h. Maximum values of μ of
about 0.04 h−1 (Stratton et al., 1998), 0.05 h−1 (Invitrogen, 2002),
and 0.02 h−1 (Tolner et al., 2006) were theoretically reached at the be-
ginning of constant methanol addition and then decreased to values of
b0.01 h−1 (Fig. 6). Proﬁles for MutS promoted lower initial speciﬁc
growth rates of around 0.02 h−1 (Stratton et al., 1998), or 0.01 h−1
(Invitrogen, 2002) and then decreased to values of b0.01 h−1. Timegen, 2002; Stratton et al., 1998; Tolner et al., 2006).First row: 3-stage culture with a batch
with glycerol and AOX1 derepression (B), and a production phase in fedbatchmode using
rresponding substrate) per initial volume in the process phase, per hour.Second row: time
for glycerol (Jungo et al., 2006) and 0.33 g g− 1 for methanol (Zhang et al., 2005). A cell
ycerol concentration was set to 40 g l− 1 in batch, and the fedbatch phase (B)was ﬁnished
glycerol (black lines) and right axis to speciﬁc growth rates onmethanol (red lines). These
ass concentrations (second row).
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concentrations in the production phase are changed due to variations in
protocols. For this calculation, an initial CDW concentration of 50 g l−1
was assumed according to Invitrogen protocols (2002) (180–220 g l−1
wet cell weight (WCW)). However, the initial feed rate, F0, can be ad-
justed to any biomass concentration according to Fig. 5.
3.3.2. Implementing customised process strategies
In recent years, protocol design has shifted from classical ‘recipes’
(Invitrogen, 2002; Stratton et al., 1998; Tolner et al., 2006) tomore con-
ceptual attempts (Maurer et al., 2006; Zalai et al., 2012; Zhang et al.,
2007). Considering the maximum speciﬁc growth rate (μmax) as the
upper limit and the production kinetics qp(μ) as an indicator of the op-
timum production range of μ, design of a customised fedbatch feed pro-
ﬁle to maximise product titre is possible (Fig. 7).
With P. pastoris as the expression host, several gram per litre of re-
combinant enzymes have been produced during fedbatch production
processes (Table 4). The highest published titres for Fab-fragments
and hormoneswere in the range of 1 g l−1 to 4 g l−1 (Table 4). However,
high product titres are partly due to high biomass concentrations and
long production times (Table 4). At the beginning of the methanol
induction-/production-phase, CDW concentrations between 20 g l−1
to 100 g l−1 were reported (Table 4). The biomass concentration at
the beginning of the production phase is a critical factor that should
be considered for optimising high-level production (Mallem et al.,
2014; Zhang et al., 2007). By Invitrogen protocols (2002), an initial
biomass concentration of 180 g l−1 to 220 g l−1 WCW, which corre-
sponds to approximately 50 g l−1 CDW, is recommended. However,
in the second edition of P. pastoris protocols 2007, Zhang et al.
(2007) recommend higher initial biomass concentrations between
150 g l−1 to 450 g l−1 WCW, corresponding to 38 g l−1 to
113 g l−1 CDW.
Up to what biomass concentrations is the recombinant protein for-
mation physiologically and practically feasible has still to be elucidated.
Furthermore, biomass separation from high cell density cultures is a
challenging task in downstream processing (Meyer and Schmidhalter,
2014). The highest ﬁnal biomass concentration reported for P. pastoris
grown on methanol, continuously added in fedbatch culture, wasFig. 7. Concept for a rational cultivation strate150 g l−1 (Curvers et al., 2001a). In fedbatch with glucose, a biomass
concentration of more than 200 g CDW l−1 was achieved (Heyland
et al., 2010).
Generally, high productivity and a high ﬁnal titre (Table 4) are
reached if cultivation occurs at a high biomass concentration, for long
periods, at a desired μ for product formation, before system boundaries
are reached (i.e., maximumbiomass concentration,maximumheat evo-
lution or oxygen supply) (Fig. 7). However, this is only the case if high
productivity is reached at low speciﬁc growth rates. AOX1-controlled
product formation typically shows higher speciﬁc productivities at
lower speciﬁc growth rates. Maximum speciﬁc productivities within
the range of 0.1 mg g−1 h−1 to 0.26 mg g−1 h−1 were reported at spe-
ciﬁc growth rates below 0.02 h−1 (Bhatacharya et al., 2007; Hang et al.,
2008; Kobayashi et al., 2000; Potgieter et al., 2010; Yamawaki et al.,
2007). GAP-controlled processes tend to exhibit high speciﬁc product
formation rates at a level comparable to AOX1-strains but for an opera-
tional μ near μmax (Fig. 2, Table 3). Along with this consideration
Buchetics et al. (2011) reverse engineered a strain with increased
GAP-controlled high product formation at low speciﬁc growth rates
(b0.1 h−1).
Established product formation kinetics has been the basis for several
attempts at rational process design and optimisation (Kobayashi et al.,
2000; Maurer et al., 2006; Zhang et al., 2005). For instance, productivity
(rp) at the end of the process was maximised using a solver-based MS-
Excel ﬁle application, by ﬁnding the best time course for a speciﬁc
growth rate and duration of the process (Maurer et al., 2006). However,
the applicationwas for GAP-controlled recombinant protein production
with a single substrate for growth and production. For AOX1-controlled
processes, biomass concentration at the start of the methanol
induction-/production-phase is variable and has to be optimised,
together with the time course for μ during the production phase
(Mallem et al., 2014; Zhang et al., 2007). A maximisation model for
AOX1-controlled processes was established by Kobayashi et al. (2000)
and Zhang et al. (2005). Optimal time courses to reachmaximumprod-
uct formation, in all three attempts, showed the following typical pro-
ﬁle: high speciﬁc growth rate at the beginning of the process to
increase biomass concentration and a subsequent decrease during the
production phase.gy based on product formation kinetics.
Table 4
Operational settings for high productivity fedbatch production processes.
cp,end
(g l−1)
Heterologous product Timea
(h)
CDWinductionb
(g l−1)
CDWend
(g l−1)
μ
(h−1)
Operation mode Substrate Promotor Strain References
Enzymes
19.55 Glucose oxidase
(Aspergillus niger)
168 100 245 NA Feedback control (MeOH
conc. at 1.8 v/v%)
Methanol/
mannitol
AOX GS115 Gu et al. (2015)
5.8 Lipase/acetyltransferase
(Escherichia coli)
119 20 74 0.01 Feed forward (exponential) Methanol AOX GS115 Brunel et al.
(2004)
3.3 Lipase
(Yarrowia lipolitica)
77 – 120 NA Feedback control (DO level
between 25–35%)
Glucose GAP X-33 Wang et al.
(2012)
~2.5 Cellobiohydrolase 2
(Trichoderma reesei)
90 – NA NA Feed forward (linear) Glucose GAP CBS7435 Mellitzer et al.
(2012)
Antibody
2.116 Fab fragment
(human antibody 3H6)
~25 – 100 0.15–0.05 Feed forward (exponential
and linear)
Glucose GAP X-33 Buchetics et al.
(2011)
1.7 IgG1 182 ~30c ~138c 0.014 Feed forward (exponential) Methanol AOX YGLY4140 Potgieter et al.
(2010)
0.198 scFv fragment
(anti-bisphenol A)
~30 ~60 ~80 NA Feedback control (MeOH
conc. at 0.5 v/v %)
Methanol AOX GS115 Yamawaki et al.
(2007)
0.046 Fab fragment
(anti-HIV antibody 2F5)
92 – 96 0.2–0.05 Feed forward (exponential
and linear)
Glucose GAP X-33 Maurer et al.
(2006)
Hormone & growth factors
3.84 Insulin precursor ~130 56 59 NA Feedback control (MeOH
conc. at 0.25 v/v %)
Methanol AOX X-33 Gurramkonda
et al. (2010)
0.97 Insulin precursor
(porcine)
80 59 ~140 0.016 Feed forward (exponential) Methanol AOX GS115 Hang et al.
(2008)
0.76 GM-CSF
(murine)
68 ~25c ~55c 0.015 Feedback control
(exponential)
Methanol AOX GlycoSwitch-Man5 Jacobs et al.
(2010)
Interferone & interleukin
0.25 rhIL-2-HSA fusion 60 – 250
(OD600)
NA Feedback control (DO level
between 25–40%)
Glucose GAP GS115 Guan et al.
(2013)
0.392 Interferone
(ovine)
70 NA ~117c 0.025–0.020 Feed forward (exponential) Methanol AOX X-33 Sinha et al.
(2003)
NA not available.
~Values approximated from ﬁgures.
a Time of product formation during fedbatch cultivation.
b Not stated for constitutive GAP-controlled product formation.
c Published parameter adapted from wet cell weight to dry cell weight by a factor of four.
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high cell density P. pastoris cultivations (Cunha et al., 2004), irrespective
of the substrate used. However, heat evolution and oxygen uptake
strongly depends on speciﬁc growth rates and, therefore, the process
must be designedwithin the technical limitations of the available equip-
ment (Fig. 7).
3.3.3. Recommendations for best practice in process development
Speciﬁc productivity (qp), maximum biomass in the reactor (x ∙ V),
and productive time (i.e., between induction and harvest) are critical
factors inﬂuencing the performance of biotechnological production pro-
cesses that aim at producing amaximum amount of product, within de-
sired quality speciﬁcations, and over a minimum time. Our collected
experience leads to the following recommendations:
• Process strategies described in the available standard protocols cover
nearly all μ-ranges typically found for optimal AOX1-controlled
product formation (Table 3). Standard Mut+ strategies (Invitrogen,
2002; Stratton et al., 1998; Tolner et al., 2006) are suitable for strains
with a μmax higher than 0.05 h−1. The MutS strategies (Invitrogen,
2002; Stratton et al., 1998) are suitable for strains with a maximum
speciﬁc growth rate higher than 0.02 h−1.
• Generally, a high initial concentration of biomass and a low speciﬁc
growth rate during production are favourable. Suitable strategies
for maximum product formation and titre show a typical pattern:
high initial speciﬁc growth rate to rapidly grow biomass to a high
concentration, and a subsequent decrease in μ during production,
preferably at the optimum μ-value for maximum productivity.• The current trend is to move away from standard protocols towards
concepts that enable an operator to adapt a particular recommenda-
tion to any speciﬁc clone/strain or bioreactor. This review attempts
to address this issue.
4. Future development
In spite of ever increasing interest in and current intensive research
on the P. pastoris system, it is still far from achieving the maturity of,
for example, E. coli or S. cerevisiae. In particular, from the process
development perspective, which is the focus of this review, attempts to
reduce the typically high workload required to determine the qp(μ)-
relationship as well as the further development of methods to enhance
the robustness of process control on amanufacturing scale are necessary.
In this chapter just a glimpse of a couple of innovative developments
are depicted: characterisation of product formation at the single-cell
level, and use of software-sensors to reduce workload and enhance
product quality (in particular of complex proteins) by control of
growth/process conditions. However, they are treated brieﬂy, since
each of these topics could be extensively reviewed on its own.
4.1. Single cell level perspective on production
Recent evidence has shown how epigenetic factors can inﬂuence the
distribution of protein production within a single population (Love
et al., 2012). A new paradigm for screening therefore needs to take
into account such information, considering the ‘best producer’ at the
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takes place. The most appropriate method of choice to screen for the
‘best producer’ in a population, ﬂuorescence activated cell sorting
(FACS), enables the identiﬁcation of satisfactory clones for several pro-
cesses (Mattanovich and Borth, 2006; Sleiman et al., 2008). However,
sorting is affected by a major limitation: secreted proteins, the most in-
dustrially appealing products, by their very nature leave the producing
cells, and a method based on intracellular ﬂuorescence might fail to se-
lect the best producer for secreted products. For intracellular or surface
proteins, FACS retains all its validity and potential. Moreover, FACS pro-
vides a picture-frame view of production capability in a single cell at a
given time; secretion, however, is a dynamic process, adapting to cell
metabolism and growth, best captured in single cells (and their proge-
ny) over time (Love et al., 2010). A compromise between the uniformity
and speed of analysis by FACS and traditional cultivation (with its loss of
information at the single cell level) is provided by the technique of
micro-engraving, an emerging method for high-throughput analysis of
secreted products from single cells (Love et al., 2006). Micro-
engraving is a soft lithographic method based on intaglio printing to
generate microarrays comprising secreted products from single cells,
and has been used for screening a variety of secreted recombinant pro-
teins (Panagiotou et al., 2011) aswell as to characterise the secretome of
B cells (Story et al., 2008). Interestingly, this method provides useful in-
sights into secretion dynamics, showing, for example, how such a pro-
cess is not linked to the cell cycle, but varies stochastically within a
single cell during cell duplication.4.2. Approaches to reduce experimental load
To support laborious and time-consuming physiological characteri-
sation of cells based on sophisticated process control, software-
sensors have been established (Brühlmann et al., 2015; Herwig et al.,
2001; Jenzsch et al., 2006; Luttmann et al., 2012). Such software-
sensors deliver information on the important real-time variables that
characterise a bioprocess (such as concentrations of substrates, prod-
ucts and biomass) and are typically determined off-line, with an expect-
ed post-sampling delay of several hours. Available on-line data led to
advanced process controls based on real-time physiological values
(i.e., speciﬁc rates of biomass growth, substrate utilization, product for-
mation etc.), and, therefore, to improved bioprocess reproducibility and
higher product quality. Besides a reduction in the experimental load,
human handling errors (e.g., from pipetting or other sampling proce-
dures) are reduced, and higher sampling frequency is achieved, which
results in enhanced bioprocess-data quality. In particular, the possibleFig. 8. Schematic presentation of different (molecular) levels of quantitative protein analyses. (e
correct glycoforms).‘automated’ determination of speciﬁc maintenance rates (ms) would
be an asset for the rational design of appropriate process strategies.4.3. Product quality
The term ‘product quality’ takes into account target attributes (both
desired and unwanted), which may belong to the following categories
(Eon-Duval et al., 2012):
• biological activity, half-life, immunogenicity and safety;
• deamination, glycation, glycosylation, oxidation, hydroxylation and
the formation of disulphide bonds, aggregation, etc.
Therefore a correctly folded and functional (active) protein, whose
post-translational modiﬁcations are both correct and sufﬁcient, is the
product (Fig. 8) that should be ﬁnally quantiﬁed to reveal true produc-
tion kinetics. For example, a correctly glycosylated protein should have
the correct human-like mannose-5 structure (i.e., as already engineered
for the P. pastoris system; Jacobs et al., 2009; Vervecken et al., 2004) and
all glyco-sites should be occupied (Haet al., 2011b). In addition, possible
degradation of the protein, both intra- and extra-cellularly, should be
considered when establishing kinetic relationships (Celik et al., 2009).
Although such sophisticated analyses are demanding and not always
available, an alternative, acceptable, mathematical description of prod-
uct formation kinetics is still lacking. A few examples of recent experi-
mental studies show and quantify effects of culture conditions such as
speciﬁc growth rate, substrate composition, temperature and oxygen
supply on correct and sufﬁcient post-translational proteinmodiﬁcations
(Ha et al., 2011a; Hesketh et al., 2013; Jacobs et al., 2010; Rebnegger
et al., 2014; Schenk et al., 2008; Seman et al., 2014; Wu et al., 2011,
2012).
Examples of complex proteins of high scientiﬁc and commercial
relevance are human membrane proteins. Although the strength of
the P. pastoris system lies in the production of secreted proteins (as
described in the previous chapters), several applications as an efﬁcient
host for intracellular production of heterologous mammalian mem-
brane proteins (MPs) have been reported in the literature (Bornert
et al., 2012; Byrne, 2015; Hedfalk, 2013; Singh et al., 2012a). Human
MPs are highly desirable for pharmaceutical research because of
their importance in human pathophysiology, but have not been readily
available in the required quantities (i.e., milligram amounts) or
crystallisation-grade quality until recently, following developments in
advanced recombinant technologies (Krettler et al., 2013)..g., from a rather non-speciﬁc total protein quantiﬁcation to quantiﬁcation of proteinswith
1191V. Looser et al. / Biotechnology Advances 33 (2015) 1177–1193A prominent example of the successful production of a stable and
functional MP in P. pastoris, which allowed its crystallisation and struc-
tural determinations, is the human heteromeric amino acid transporter
4F2hc/LAT2 (Costa et al., 2013; Meury et al., 2014). Heteromeric amino
acid transporters (HATs) are common to all kingdoms of life, and are
composed of two different subunits (heavy and light chains, 4F2hc
and LAT2 respectively) linked by a conserved disulphide bridge
(Fotiadis et al., 2013). The heterodimer 4F2hc/LAT2 was successfully
overexpressed in P. pastoris, strain KM71H, including the required
post-transcriptional modiﬁcations by co-transformation of both sub-
units (Costa et al., 2013; Rosell et al., 2014). However, the correct (and
stoichiometric) linkage of the subunits by the disulphide bridge was
affected by culture conditions, as studied systematically in bioreactor
cultures (unpublished results). Finally, MPs are one of the emerging
applications of the P. pastoris system,where use of the concepts outlined
in this review may become relevant.
5. Conclusions
The aim of this review is to establish the main principles for both
comparison and development of biotechnological production processes
with P. pastoris. The conclusions, which follow a trend away from
standardised recipes to a concept transferable between both different
strains and bioreactor systems, are drawn from multiple perspectives,
and in particular highlight cell physiology, product classes, promoters,
and the process strategies applied. To achieve this, a multitude of pub-
lished data was analysed, evaluated (recalculated) and compared.
Moreover, the ‘recommendation’ paragraphs closing each subchap-
ter are of practical relevance by guiding the reader through best prac-
tices for bioprocess design, which comprise the aspects of strain/clone
screening, strain physiological characterisation and implementation of
a fedbatch process strategy. Particularly highlighted is the rationale for
why results from screening in micro-titre plates are only rarely directly
transferable to production processes in bioreactors.
Our aim is to foster a greater understanding of scalable, and thus
transferable process characteristics. The relationship between biomass
growth and protein production, which results from both genetic strain
construction and culture conditions, is the basis for a rational design of
an optimum process strategy speciﬁc to a combination of a particular
product and genetic construct. The observed time course concentrations
of secreted proteins typically resulted from balanced ﬂows through tran-
scription, translation, folding and degradation. They were used, together
with time courses of biomass concentrations, as a basis for determining
production kinetics. This review uniquely compares processes/strains
on the basis of production kinetics (i.e., the relationship between speciﬁc
growth rate, μ, and speciﬁc productivity, qp) instead of commonly used
titers, i.e., ﬁnal product concentrations, which do not reveal information
on biomass concentration, speciﬁc productivity or process duration; they
are therefore not directly comparable between different processes,
strains or bioreactor systems. A deeper understanding of the underlying
concepts of process comparison and development has become increas-
ingly relevant as new genetic constructs are made available.
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